| Drug ID: | Drug148 |
|---|---|
| Drug Name: | Upadacitinib |
| CID: | 58557659 |
| DrugBank ID: | DB15091 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT06780683, , NCT06274996, , NCT05782907, , NCT06095596, , NCT03653026, , NCT02819635, , NCT03345836, , NCT05867329 |
| Molecular Formula: | C17H19F3N6O |
| Molecular Weight: | 380.4 g/mol |
| Isomeric SMILES: | CC[C@@H]1CN(C[C@@H]1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F |
| Synonyms: | Upadacitinib; ABT-494; Rinvoq; Upadacitinib anhydrous; UNII-4RA0KN46E0; 4RA0KN46E0; ABT 494; ABBV-599 COMPONENT UPADACITINIB; 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo(1,2-a)pyrrolo(2,3-e)pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-; REL-(-)-(3S,4R)-3-ETHYL-4-(3H-IMIDAZO(1,2-A)PYRROLO(2,3-E)PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE |
| Phase 0: | 1 |
| Phase 1: | 6 |
| Phase 2: | 17 |
| Phase 3: | 49 |
| Phase 4: | 10 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt1172 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | None | |
| dt1173 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibitor | |
| dt1174 | 58557659 | Upadacitinib | 3716 | JAK1 | Homo sapiens (human) | Inhibition | |
| dt1175 | 58557659 | Upadacitinib | 3717 | JAK2 | Homo sapiens (human) | Inhibition | |
| dt1176 | 58557659 | Upadacitinib | 3718 | JAK3 | Homo sapiens (human) | Inhibition | |
| dt1177 | 58557659 | Upadacitinib | 7297 | TYK2 | Homo sapiens (human) | Inhibitor | |
| dt1178 | 58557659 | Upadacitinib | 1565 | CYP2D6 | Homo sapiens (human) | None | |
| dt1179 | 58557659 | Upadacitinib | 3716 | JAK1 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT07442045 | Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis | NULL | RECRUITING | Sixth Affiliated Hospital, Sun Yat-sen University | Ulcerative Colitis (UC) | DRUG: Upadacitinib|DRUG: Vedolizumab | Details |
| NCT05496348 | Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | NULL | RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT05494606 | An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice | NULL | ACTIVE_NOT_RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT07138898 | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty | PHASE2 | NOT_YET_RECRUITING | NYU Langone Health | Rheumatic Disease | DRUG: Methotrexate|DRUG: Sulfasalazine|DRUG: Hydr… | Details |
| NCT07073079 | A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting | NULL | RECRUITING | AbbVie | Crohn's Disease | None | Details |
| NCT03653026 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis | PHASE3 | COMPLETED | AbbVie | Ulcerative Colitis (UC) | DRUG: Placebo|DRUG: Upadacitinib | Details |
| NCT06922331 | Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis | NULL | COMPLETED | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn's Disease (CD)|Ulcerative Colitis (UC)|… | DRUG: Upadacitinib | Details |
| NCT03345849 | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | PHASE3 | COMPLETED | AbbVie | Crohn's Disease | DRUG: Upadacitinib|DRUG: Placebo for Upadacitinib | Details |
| NCT03345836 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | PHASE3 | COMPLETED | AbbVie | Crohn's Disease | DRUG: Matching Placebo for Upadacitinib|DRUG: Upa… | Details |
| NCT03345823 | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | PHASE3 | ACTIVE_NOT_RECRUITING | AbbVie | Crohn's Disease | DRUG: Upadacitinib|DRUG: Placebo for Upadacitinib | Details |
| NCT03006068 | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | PHASE3 | ACTIVE_NOT_RECRUITING | AbbVie | Ulcerative Colitis (UC) | DRUG: Upadacitinib (ABT-494)|DRUG: Placebo | Details |
| NCT06838845 | An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | NULL | RECRUITING | AbbVie | Ulcerative Colitis | None | Details |
| NCT02819635 | A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2|PHASE3 | COMPLETED | AbbVie | Ulcerative Colitis (UC) | DRUG: Placebo|DRUG: Upadacitinib | Details |
| NCT02782663 | A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease | PHASE2 | COMPLETED | AbbVie | Crohn's Disease (CD) | DRUG: ABT-494 | Details |
| NCT06780683 | Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease | NULL | RECRUITING | Xiang Gao | Inflammatory Bowel Disease|Crohn's Disease|Ulcera… | DRUG: Upadacitinib | Details |
| NCT06660693 | Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis | PHASE3 | RECRUITING | McMaster University | Colitis, Ulcerative | DRUG: Upadacitinib Oral Product | Details |
| NCT06581042 | Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium | NULL | RECRUITING | AbbVie | Ulcerative Colitis|Crohn's Disease | None | Details |
| NCT06573944 | IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study | NULL | UNKNOWN | The Third Xiangya Hospital of Central South University | Crohn's Disease|Upadacitinib|Intestinal Ultrasoun… | None | Details |
| NCT06520397 | Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease | PHASE4 | RECRUITING | Sixth Affiliated Hospital, Sun Yat-sen University | Crohn Disease | DRUG: Ustekinumab and Upadacitinib|DRUG: Ustekinu… | Details |
| NCT06498167 | Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) | NULL | RECRUITING | Universidade do Porto | Inflammatory Disease|Drug Side Effect|Drug Use|Ad… | DRUG: Upadacitinib | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Herpes zoster in patients with inflammatory arthritides or ulcerative colitis t…
PMID: 36635577
Year: 2023
Relationship Type:
Clinical Trial
Score: 6.5
JAK inhibitors (JAKi) are new targeted-synthetic drugs, approved for various immune-mediated inflammatory diseases (IMIDs), including inflammatory ar…
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in…
PMID: 36571701
Year: 2023
Relationship Type:
Clinical Trial
Score: 6.5
BACKGROUND AND OBJECTIVE: Upadacitinib, an oral selective and reversible Janus kinase (JAK) inhibitor, showed favorable efficacy and safety in patien…
The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduc…
PMID: 36515243
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Janus kinase (JAK) 1 inhibitor upadacitinib and IL-23 inhibitor risankizumab are efficacious in inflammatory bowel disease (IBD) patients…
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of I…
PMID: 36464141
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND & AIMS: We evaluated the efficacy of once-daily (QD) upadacitinib 45 mg, an oral, reversible Janus kinase inhibitor, on early symptomatic …
Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's D…
PMID: 36272109
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and is under evaluation for the mana…
Management of Axial Spondyloarthritis - Insights into Upadacitinib
PMID: 36268520
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Although the pathogenesis of spondyloarthritis (SpA) has still not been elucidated our options to treat SpA have definitely improved in the last deca…
In active UC, upadacitinib induced and maintained remission
PMID: 36191310
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results …
Upadacitinib (Rinvoq): A second JAK inhibitor for ulcerative colitis
PMID: 36094554
Year: 2022
Relationship Type:
Association
Score: 6.5
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerativ…
PMID: 35747444
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Upadacitinib is a selective small molecule that inhibits Janus kinase (JAK) type 1. This molecule is administrated orally and is currently approved f…
Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a …
PMID: 35695972
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Upadacitinib is a selective JAK-1 inhibitor approved for the treatment of rheumatoid arthritis and more recently, ulcerative colitis. Phase II trials…
Upadacitinib as induction and maintenance therapy for moderately to severely ac…
PMID: 35644166
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: There is a great unmet need for advanced therapies that provide rapid, robust, and sustained disease control for patients with ulcerative…
Upadacitinib in refractory ulcerative colitis
PMID: 35548867
Year: 2022
Relationship Type:
Treatment
Score: 6.5
We report the first clinical-practice case to date of treatment with upadacitinib for ulcerative colitis, prior refractoriness to all therapeutic opt…
Simultaneous measurement of upadacitinib and methotrexate by UPLC-MS/MS and its…
PMID: 34875493
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Upadacitinib, as a selective and reversible Janus kinase (JAK) inhibitor, has been widely used in the treatment of atopic dermatitis, ulcerative coli…
Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, a…
PMID: 34107013
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: Bowel urgency and abdominal pain are impactful, yet under-appreciated ulcerative colitis symptoms and not commonly assessed in c…
Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinas…
PMID: 34042156
Year: 2021
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Janus kinase (JAK) inhibition shows promise for treatment of patients with moderate to severe Crohn's disease. We aimed to provide mechan…
Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b …
PMID: 33755884
Year: 2021
Relationship Type:
Clinical Trial
Score: 6.5
INTRODUCTION: In the phase 2 CELEST study, positive efficacy results were obtained with the Janus kinase 1 inhibitor upadacitinib for adult patients …
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a revie…
PMID: 33240390
Year: 2020
Relationship Type:
Treatment
Score: 6.5
The Janus kinases (JAK) are a group of molecules, composed of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), which are key components within the JAK…
A review of upadacitinib in rheumatoid arthritis
PMID: 32530345
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Rheumatoid arthritis (RA) is a chronic inflammatory disease primarily affecting the joints and is associated with significant levels of disability an…
Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's …
PMID: 31594037
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Upadacitinib plasma concentrations, efficacy, and safety data from 216 subjects with moderate-to-severe active Crohn's disease (CD) from the 16-week …